Alliancebernstein L.P. Allogene Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 210,078 shares of ALLO stock, worth $296,209. This represents 0.0% of its overall portfolio holdings.
Number of Shares
210,078
Previous 210,078
-0.0%
Holding current value
$296,209
Previous $588,000
23.98%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ALLO
# of Institutions
170Shares Held
132MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$26.4 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$23.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$11.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$9.89 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$9.72 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $203M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...